Rezolve AI clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Rezolve AI PLC
RZLV · Nasdaq · USD · Market cap $617M · 573 employees
Rezolve AI PLC provides generative AI solutions for the retail and e-commerce sectors in the United Kingdom and the United States.
Not yet scoredPrice as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 04:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price1.22 USD at the 5 Nov 2026 close
- Our regime readDistribution, as of 7 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.20)
- Last reviewed5 Nov 2026 (2 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-05).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.20, read 2026-11-05
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Rezolve AI PLC holds its Distribution at $1.22. The statistical read favours the sellers, held for 47 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 47 days |
| Price at the screen | $1.22 |
| Valuation | N/A trailing · N/A forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | -0.07 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 25.71% | Below 33% | Interest-bearing debt is just 25.7% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 23.75% | Below 49% | Money owed to the company is 23.7% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Rezolve AI clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Rezolve AI clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 26%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
How a fair value is estimated: discounted cash flow (DCF).
The Street's RangeThird-party analyst targets: 4 covering, consensus Strong Buy. The average target sits +638% from the screen price.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| EPS, trailing | -0.48 |
| Revenue growth | +1,970.4%growing very fast |
| Profit margin | -106.9%currently unprofitable |
| Return on equity | -94.4%not currently earning a positive return on equity |
| FCF yield | -1.80% |
| Debt to equity | 0.43minimal debt: a conservative balance sheet |
| Current ratio | 0.49below 1: short-term bills exceed liquid assets |
| Beta | -0.07barely tracks the market's swings |
| Short interest, float | 0.15% |
| 52-week range | 1.46 - 5.00 |
| Market cap | $617M |
| Employees | 573 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to United Kingdom and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeRZLV trades on Nasdaq (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it none, with a mean price target of $11.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 20.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it none, with a mean price target of $11.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 13.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it none, with a mean price target of $11.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it none, with a mean price target of $11.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it none, with a mean price target of $11.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it none, with a mean price target of $11.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 13.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it none, with a mean price target of $11.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it none, with a mean price target of $11.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Rezolve Ai to Participate in the Maxim Growth Summit 2026 Yahoo Finance · 26d ago
- Cantor Fitzgerald Thinks This Little-Known AI Stock Is Set to Soar 300% Yahoo Finance · 27d ago
- Rezolve Ai Opens Retail to Any AI Shopping Agent with RezolvePay, Targeting a Multi-Trillion-Dollar Commerce Opportunity Yahoo Finance · 29d ago
- Stocktwits Fintech Pulse: US Fintech Weekly Briefing & Market Drivers Yahoo Finance · 29d ago
- Rezolve AI (RZLV) Stock May Trade At A Discount After AI Commerce Push Yahoo Finance · 7 Oct 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $2.72 | -12.1% | · | $879 | -12.1% |
| 2 months | $2.38 | +0.4% | · | $1,004 | +0.4% |
| 3 months | $2.73 | -12.5% | · | $876 | -12.5% |
| 6 months | $2.66 | -10.2% | · | $899 | -10.2% |
| 1 year | $2.05 | +16.6% | · | $1,166 | +16.6% |
| 2 years | $11.55 | -79.3% | · | $207 | -79.3% |
| 3 years | $10.24 | -76.7% | · | $233 | -76.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever RZLV does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.